| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 31, 2008
Accepted on August 4, 2008
John H. Stroger Jr. Hospital of Cook County & Rush Medical College, Chicago, IL; Walsall Manor Hospital NHS Trust, Walsall, UK; University of Milan & IRCCS Policlinico San Donato, Italy; Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK; Queen Elizabeth Hospital, Hong Kong SAR; Keele University and North Staffordshire Hospital, Stoke on Trent, UK; Hacettepe University, Ankara, Turkey; IRCCS G. Gaslini, University of Genova, Italy; Cincinnati Children's Hospital Medical Center & University of Cincinnati, OH; Christchurch Hospital, New Zealand; Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Israel
* To whom correspondence should be addressed. E-mail: rasa_kazlauskaite{at}rush.edu.
Context: Diagnostic value of tests for detecting hypothalamic-pituitary adrenal insufficiency (HPAI) is controversial.
Objective: To compare standard-dose and low-dose corticotropin tests for diagnosing HPAI.
Data Sources: PubMed database from 1966 to 2006 for studies reporting diagnostic value of standard-dose or low-dose corticotropin tests, with patient-level data obtained from original investigators.
Study Selection: Eligible studies had more than 10 patients; all subjects were evaluated because of suspicion for chronic HPAI; and patient-level data was available. We excluded studies with no accepted reference standard for HPAI (insulin hypoglycemia or metyrapone test), if test subjects were in the intensive care unit, or if only normal healthy subjects were used as controls.
Data Extraction: We constructed receiver operator characteristic (ROC) curves using patient-level data from each study, and then merged results to create summary ROC curves, adjusting for study size and cortisol assay method. Diagnostic value of tests was measured by calculating area under the ROC curve (AUC) and likelihood ratios.
Data Synthesis: Patient-level data from 13 of 23 (57%) studies (679 subjects) were included in the meta-analysis. The areas under the ROC curves were: low-dose corticotropin test 0.92 (95% CI: 0.89–0.94), and standard-dose corticotropin test 0.79 (95% CI: 0.74–0.84). Among patients with paired data (7 studies, 254 subjects), diagnostic value of low-dose corticotropin test was superior to standard-dose test, AUC 0.94 and 0.85, respectively (P<0.001).
Conclusions: Low-dose corticotropin test was superior to standard-dose test for diagnosing chronic HPAI, however it has technical limitations.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |